| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424140100 | Extracorporeal or ex vivo removal of antibodies or immune complexes (e.g., removal of autoantibodies, etc.); or extracorporeal or ex vivo removal of antigen by antibodies (e.g., removal of cancer cells from bone marrow by antibodies, etc.) | 22 |
| 20080286278 | Process for in vivo treatment of specific biological targets in bodily fluids - A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent, wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent. | 11-20-2008 |
| 20090246203 | METHOD FOR IMMUNOADSORPTION BY MEANS OF AUTOANITGENS - The invention relates to a novel method for immunoadsorption therapy of human autoimmune diseases by means of immobilized or fixed autoantigens. | 10-01-2009 |
| 20100098698 | TARGETED APHERESIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound out and the cleaned blood is returned to the patient Removal of circulating RF and immune complexes will ameliorate the symptoms of rheumatoid arthritis. | 04-22-2010 |
| 20100278832 | ANTI-BST2 ANTIBODY - BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D. | 11-04-2010 |
| 20110020358 | Methods and Compositions for Detecting Amyotrophic Lateral Sclerosis - The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention. | 01-27-2011 |
| 20110038872 | METHODS OF DIAGNOSING AND TREATING AUTISM - The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers. | 02-17-2011 |
| 20110044989 | Zona Pellucida Binding Peptides, Expression Vectors, Compositions, and Methods for Species Specific Immunocontraception of Animals - Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines. | 02-24-2011 |
| 20110086036 | COMPOSITION COMPRISING VLP AND AMYLOID BETA PEPTIDE - The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A□-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the A | 04-14-2011 |
| 20110091471 | TREATMENT METHOD FOR EPITHELIAL CANCEROUS ORGANISM - It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising:
| 04-21-2011 |
| 20110129479 | IMMUNOGEN SELECTION DIRECTED IN IMMUNOGLOBULIN PACKAGES IN PLASMA AND COLOSTRUM AND METHOD OF MAKING AND USING SAME - A method for the selection and production of group specific immunoglobulins to bind to specific microbes or their toxins is provided. The immunoglobulins are produced in animals and collected either in the plasma or colostrums of the animals after being challenged with a series of selected immunogens. The selected immunoglobulins are packaged into products against specific groups of microbes or their toxins. These packages are delivered to animals including humans. These products could be used as passive protectants. The packages could be developed into products to protect animals or humans against diseases until vaccines can be effectively administered. | 06-02-2011 |
| 20110171226 | Novel Subtype of Closteridium Botulinum Neurotoxin Type A and Uses Thereof - A novel subtype of type A botulinum neurotoxin (BoNT/A) is disclosed in the application. Methods to purify the neurotoxin as well as uses thereof are also disclosed. | 07-14-2011 |
| 20120093825 | METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN - Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated. | 04-19-2012 |
| 20120294865 | Integrin Alpha-2 Binding Agents and Use Thereof to Inhibit Cancer Cell Proliferation - The invention provides an integrin alpha-2 binding agent and methods of using an integrin alpha-2 binding agent to, e.g., inhibit proliferation of cancer cells, modulate tumor growth in a subject, inhibiting angiogenesis, or treating a fibrotic disorder. The invention further provides a method of producing an antibody, the method comprising propagating cancer cells in a 3-dimensional matrix; immunizing a mammal with the propagated cancer cells; and isolating an antibody from the immunized mammal. A method of identifying an agent that inhibits cancer cell proliferation also is provided. | 11-22-2012 |
| 20140161810 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 06-12-2014 |
| 20140294850 | EARLY CHILDHOOD MEMBRANOUS NEPHROPATHY DUE TO CATIONIC BOVINE SERUM ALBUMIN - The invention concerns a biomarker for diagnosing or prognosing childhood Membranous Nephropathy (MN), said biomarker is (i) cationic Bovine Serum Albumin (BSA), and/or (ii) an antibody that binds to a polypeptide of sequence SEQ ID NO: 3. The invention further concerns an antibody or antibody fragment or a composition comprising such an antibody or antibody fragment, wherein said antibody or antibody fragment is specific to an amino acid sequence SEQ ID NO: 3. The invention also concerns a foodstuff likely to contain BSA or cow milk or cow milk extracts, wherein said foodstuff is depleted in BSA. | 10-02-2014 |
| 20150071935 | Treatment for the rapid amelioration of clinical depression - The present invention relates to an article and method of extracorporeal treating a patient's body fluid, for example, CSF (cerebrospinal fluid), lymph, or blood. The treatment includes a plurality of stages comprising removing the body fluid from a patient, applying an extracorporeal treatment to the body fluid, and returning the body fluid to the patient. In the first stage of the treatment, the body fluid is removed from the patient. A convenient method for removing blood is utilizing standard venipuncture technique. A convenient method for removing CSF is using a standard lumbar puncture. In the second stage, a treatment is applied to the body fluid. The treatment can include an antibody directed against targeted antigen(s)/TA(s). The third stage comprises returning the body fluid to the patient, and can also include removing the treatment from the body fluid. | 03-12-2015 |
| 20150079098 | Method of treating cancer - A method is described to treat cancer by extracorporeally treating a bodily fluid of a patient. A patient's body fluid is treated extracorporeally using a moiety that targets an antigen in the bodily fluid. The treatment can include applying an anti-angiogenesis, anti-tumorigenesis, anti-metastasis, or chemotherapeutic treatment to at least one antigen in the bodily fluid. The moiety facilitates removal of the antigen. The cleansed body fluid is then returned to the patient. | 03-19-2015 |
| 20150132312 | SYSTEMS AND METHODS FOR EXTRACORPOREAL BLOOD MODIFICATION - The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases. | 05-14-2015 |
| 20150291661 | AGONISTIC AUTOANTIBODIES TO THE ALPHA1-ADRENERGIC RECEPTOR AND THE BETA2-ADRENERGIC RECEPTOR IN ALZHEIMER'S AND VASCULAR DEMENTIA - The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia. | 10-15-2015 |
| 20150352274 | DIAGNOSIS, MONITORING, AND TREATMENT - Some aspects of the invention include methods of treating a patient who has or is at risk of developing kidney disease, methods of selecting a suitable regimen for the prevention or treatment of kidney disease, and to methods of monitoring the effectiveness of a treatment regimen for the prevention or treatment of kidney disease. Other aspects of the invention include medical uses of a binding partner for an anti-IQCJ antibody, and methods of preventing or treating kidney disease in a subject using such binding partners. Still other aspects of the invention include devices for the extracorporeal treatment of a patient's blood. | 12-10-2015 |
| 20160161497 | DIAGNOSTIC METHOD FOR PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME (PANS) AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCI INFECTION (PANDAS) - The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined. | 06-09-2016 |
| 20190144565 | ANTI-IgE ANTIBODIES | 05-16-2019 |
